7 results about "Chlorothiazide" patented technology

The invention discloses a telmisartan and hydrochlorothiazide compound tablet which is characterized in that the telmisartan and hydrochlorothiazide compound tablet comprises a double-layer tablet A and a double-layer tablet B, and the layer A is prepared from telmisartan lipidosome, a diluent and a lubricant; and the layer B is prepared from hydrochlorothiazide, a diluent, a disintegrating agent, a lubricant and an antioxidant. The telmisartan liposome comprises lipid and telmisartan, the dosage ratio of the lipid to the telmisartan is (0.5-2.3): 1, the lipid comprises phospholipid and cholesterol, and in the lipid, the content of the cholesterol accounts for 20%-60% of the total amount of the lipid. The telmisartan liposome comprises lipid, telmisartan and a PH buffer solution, and the PH of the PH buffer solution is 5-7. According to the telmisartan and hydrochlorothiazide compound tablet prepared by the invention, the telmisartan dissolution is good, and the tablet is safe and stable.

The invention relates to novel application of chlorothiazide, in particular to a bacterial cell membrane bionic nano-drug loaded with an ROS responsive chlorothiazide prodrug and application of the bacterial cell membrane bionic nano-drug. The invention relates to novel application of chlorothiazide and bionic nano-drugs in preparation of drugs for treating inflammatory bowel diseases. The inventor finds for the first time that the Chl active compound can directly drive phenotype reversal of macrophages from M1 to M2 and synchronously repair intestinal mucosal barriers, and breaks the pathogenic closed loop of barrier destruction-inflammation aggravation; however, the colon targeting property is poor, the water solubility is low, and the whole body exposure is limited. Therefore, according to the application, Chl is transformed into an ROS responsive prodrug (CH NPs), and the ROS responsive prodrug (CH NPs) is coated with a cell membrane of an escherichia coli Nissle1917 strain, so that the bionic nanoparticles (CHM NPs) are constructed. The system not only retains the ROS responsiveness of CH NPs, but also obviously improves the targeting ability and residence time of the nanoparticles in a colon area by virtue of the biological characteristics of the bacterial membrane.

The present application relates to the technical field of hyperuricemia modeling, and particularly relates to a method for inducing and constructing a cynomolgus monkey hyperuricemia model and application thereof, comprising the following steps: S1: selecting male cynomolgus monkeys as model animals; S2: administering an inducing agent to the experimental animals, wherein the inducing agent is composed of hydrochlorothiazide, potassium oxonate and adenine. The inducing agent is added to ordinary monkey feed for normal feeding of the experimental animals, the intake dose of hydrochlorothiazide is 0.1 g / kg / day, the intake dose of potassium oxonate is 0.2 g / kg / day, the intake dose of adenine is 0.1 g / kg / day, and 10% fructose water is used to replace ordinary drinking water at the same time. The present application can induce a stable hyperuricemia state in the cynomolgus monkey body by means of dietary induction, combined use of hydrochlorothiazide, potassium oxonate and adenine, compared with a traditional model induced by a single intraperitoneal injection of a drug, the present application better simulates the pathogenic cause of human hyperuricemia, and is easier to operate.

The invention discloses a method for determining the content of formaldehyde in a hydrochlorothiazide bulk drug, which comprises the following steps: precisely weighing a formaldehyde solution, adding acetonitrile, an acetonitrile solution of 2, 4-dinitrophenylhydrazine and a phosphoric acid solution, and diluting to prepare a reference substance solution; the method comprises the following steps: precisely weighing a hydrochlorothiazide bulk drug, adding acetonitrile, an acetonitrile solution of 2, 4-dinitrophenylhydrazine and a phosphoric acid solution, and diluting to prepare a test solution; the method comprises the following steps: precisely measuring an acetonitrile solution of 2, 4-dinitrophenylhydrazine, a phosphoric acid solution and 1ml of acetonitrile, and diluting with acetonitrile to prepare a blank solution; analyzing by adopting high performance liquid chromatography, precisely measuring the blank solution, the test solution and the reference substance solution, respectively injecting into a liquid chromatograph, recording chromatograms, and calculating by peak area according to an external standard method to obtain the content of formaldehyde in the hydrochlorothiazide bulk drug. The method has the remarkable effects that the method has the characteristics of simple process, low use cost, good precision, high accuracy and the like, and the content of formaldehyde in the hydrochlorothiazide bulk drug can be rapidly measured.

The invention provides an irbesartan solid dispersion and a preparation method of a preparation thereof, and belongs to the technical field of pharmaceutical preparations, the irbesartan solid dispersion is prepared from 10-30% by weight of irbesartan, 60-90% by weight of copovidone and 5-15% by weight of a plasticizer by adopting a twin-screw hot melt extrusion process, and the irbesartan solid dispersion is prepared from the preparation method of the irbesartan solid dispersion and the preparation of the irbesartan solid dispersion. And mixing the solid dispersion with a filling agent, a disintegrating agent and a lubricating agent which are conventional in pharmaceutics to prepare irbesartan unilateral tablets, or additionally adding hydrochlorothiazide and mixing to prepare irbesartan compound tablets. According to the irbesartan tablet and the preparation method thereof, irbesartan is prepared into the solid dispersion and then prepared into the tablet, so that the electrostatic agglomeration of irbesartan is improved to improve the mixing uniformity of the preparation, the dissolution performance of irbesartan is remarkably improved, and the bioavailability of the medicine is improved; therefore, the problems of insufficient subsequent mixing uniformity caused by electrostatic agglomeration in irbesartan preparation preparation and poor dissolution performance and low bioavailability caused by low solubility are effectively solved.

The application discloses a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide and a preparation method thereof. The triple combination preparation comprises three active ingredients of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide, and further comprises pre-gelatinized starch, silicified microcrystalline cellulose, cross-linked carboxymethyl cellulose, polylactic acid spray-dried powder and tocopherol as auxiliary materials. The triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide is coated to obtain olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide tablets, which have the same dissolution stability as the original research product, a very smooth surface, no indentation and more stable quality.

This invention discloses a method for purifying hydrochlorothiazide, comprising dissolving crude hydrochlorothiazide in a mixture containing acid and solvent under heating conditions; then neutralizing with alkali under cooling conditions; and finally obtaining purified hydrochlorothiazide by cooling, crystallization, and filtration. The method provided by this invention further improves both the quality and purification yield of the hydrochlorothiazide product.